Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Onkure Therapeutics Inc OKUR

Healthcare Biotechnology
OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The... see more

Recent & Breaking News (NDAQ:OKUR)

Reneo Pharmaceuticals to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)

GlobeNewswire June 30, 2022

Reneo Pharmaceuticals Reports First Quarter 2022 Financial Results

GlobeNewswire May 10, 2022

Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

GlobeNewswire March 23, 2022

Reneo Pharmaceuticals Announces Senior Leadership Promotions

GlobeNewswire March 7, 2022

Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference

GlobeNewswire February 2, 2022

Reneo Pharmaceuticals Announces Changes to its Board of Directors

GlobeNewswire January 24, 2022

Reneo Pharmaceuticals Reports Third Quarter 2021 Financial Results

GlobeNewswire November 11, 2021

Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences

GlobeNewswire November 1, 2021

Reneo Pharmaceuticals Announces Notice of Allowance for Patent Application on REN001

GlobeNewswire October 14, 2021

Reneo Pharmaceuticals Appoints Ashley Hall as Chief Development Officer

GlobeNewswire October 11, 2021

Reneo Pharmaceuticals Hosting Key Opinion Leader Webinar on McArdle Disease and other Genetic Mitochondrial Myopathies

GlobeNewswire September 28, 2021

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire September 9, 2021

Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results

GlobeNewswire August 11, 2021

Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study

GlobeNewswire July 28, 2021

Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction

GlobeNewswire July 9, 2021

Reneo Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference

GlobeNewswire July 7, 2021

Reneo Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices

GlobeNewswire June 29, 2021

Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results

GlobeNewswire May 20, 2021

Reneo Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire May 19, 2021

Reneo Pharmaceuticals Announces Pricing of Initial Public Offering

GlobeNewswire April 8, 2021